Chardan Capital Rates ProQR Therapeutics (PRQR) buy

On June 26, 2026, Chardan Capital analyst Keay Nakae reiterated a Buy rating for ProQR Therapeutics N.V. (PRQR) on the NasdaqCM. The firm set a price target of $3.00, suggesting significant room for growth from the stock's current levels. This move comes as the company continues to focus on its specialized RNA editing technology for genetic diseases.

Chardan Capital vs. Wall Street Views

While Chardan Capital is optimistic with its $3.00 target, other firms on Wall Street are even more bullish. On October 1, 2026, H.C. Wainwright & Co. maintained a Buy rating but lowered its target to $8.00 from a previous $12.00. B of A Securities recently initiated coverage on August 20, 2026, with a Buy rating and an $8.00 target. Earlier in the summer, on June 29, 2026, Evercore ISI Group raised its price target from $5.00 to $6.00 while keeping an Outperform rating. Jones Trading remains the most aggressive bull in the group, maintaining a Buy rating with a $10.00 target as of June 26, 2026. Across nine analysts, the average price target sits at $8.22, which is well above the $3.00 set by Chardan Capital.

ProQR Stock Performance

On Saturday, shares of ProQR Therapeutics were priced at $1.83. The stock has been trading in a fairly tight range lately, staying above its 52-week low of $1.33 but remaining below its yearly high of $3.10. Its current price is just under the 50-day moving average of $1.94, which is a common technical measure of short-term momentum. However, it stays slightly above the 200-day moving average of $1.77, which suggests the longer-term trend is still holding steady. With a market capitalization of about $262.5 million, the company is a smaller player in the biotech space.

Recent Earnings and Financial Health

ProQR reported revenue of $18.42 million in its most recent filing, showing revenue growth of 1.204. Like many clinical-stage biotech companies, ProQR is not yet profitable, reporting a net margin of -2.28 and a return on equity of -0.57. Because it has not yet reached profitability, the company does not have a meaningful P/E ratio. Investors looking for the next update on the company's finances can expect the next earnings report on November 5, 2026.

Insider Buying and Selling at ProQR Therapeutics N.V.

There has been recent activity from within the company's own leadership. On June 26, 2026, insider Bart Filius purchased 150,000 shares at an average price of $1.54. This transaction was valued at approximately $231,000. This purchase was not made under a pre-planned Rule 10b5-1 trading plan, which often signals a direct decision to increase a personal stake based on current market conditions.

RNA Technology Focus

ProQR Therapeutics is a biotechnology company based in the Netherlands that works on finding treatments for genetic disorders. Instead of changing DNA, they use a platform called Axiomer to edit RNA, which acts as the messenger in the body's cells. Their main projects include treatments for cholestatic liver diseases and Rett syndrome. Their work is supported by a research partnership with Eli Lilly and Company, which helps them develop new medicines for the liver and nervous system.

What to Watch at ProQR Therapeutics N.V.

Investors should keep an eye on the upcoming earnings date in November for updates on the company's cash runway and clinical progress. While the Chardan Capital reiteration is a vote of confidence, the wide gap between their $3.00 target and the $8.22 consensus average shows that analysts have very different expectations for how quickly ProQR's RNA platform will pay off. As with all biotech stocks, future performance will likely depend on data from clinical trials and the success of its partnership with Eli Lilly.